Caforio Giovanni
Board Chair and CEO at BMY
- Sold, on record
- $46.8M
- Dollars the filings state
- Form 4 sales
- 19
- Latest Feb 6, 2023
- Form 144 notices
- 0
- Proposed sales
- Companies
- 1
- Filed as an executive or holder
Companies
- BMYBRISTOL MYERS SQUIBB COBoard Chair and CEO
Sales by reason
Form 4 sales per month, last 12 months.
Timeline
- 1 Form 4 sale BMYPlan not statedAug 2, 2021 2021
Sold 20,000 shares at $68.58 ($1.4M)
Caforio Giovanni, Chairman and CEO
Sold 3.8% of holdings ($36.3M position)508,980 shares leftFiling
- 2 Form 4 sale BMYPlan not statedSep 20, 2021 +49 days
Sold 25,000 shares at $60.64 ($1.5M)
Caforio Giovanni, Board Chair and CEO
Sold 4.9% of holdings ($30.9M position)483,980 shares left1x usual sizeFiling
- 3 Form 4 sale BMYPlan not statedFeb 24, 2022 +157 days
Sold 30,000 shares at $67.00 ($2M)
Caforio Giovanni, Board Chair and CEO
Sold 6.2% of holdings ($32.4M position)453,455 shares left1.2x usual sizeFiling
- 4 Form 4 sale BMYPlan not statedMar 21, 2022 +25 days
Sold 25,000 shares at $71.52 ($1.8M)
Caforio Giovanni, Board Chair and CEO
Sold 4.1% of holdings ($43.4M position)581,524 shares left1x usual sizeFiling
- 5 Form 4 sale BMYPlan not statedJun 13, 2022 +84 days
Sold 30,000 shares at $74.04 ($2.2M)
Caforio Giovanni, Board Chair and CEO
Sold 5.2% of holdings ($43M position)551,104 shares left1.2x usual sizeFiling
- 6 Form 4 sale BMYPlan not statedSep 15, 2022 +94 days
Sold 50,000 shares at $71.84 ($3.6M)
Caforio Giovanni, Board Chair and CEO
Sold 9.1% of holdings ($39.6M position)501,104 shares left2x usual sizeFiling
- 7 Form 4 sale BMYPlan not statedSep 20, 2022 +5 days
Sold 25,000 shares at $69.71 ($1.7M)
Caforio Giovanni, Board Chair and CEO
Sold 5% of holdings ($34.9M position)476,104 shares left1x usual sizeFiling
- 8 Form 4 sale BMYUnusualFeb 6, 2023 +139 days
Sold 240,000 shares at $74.65 ($17.9M)
Caforio Giovanni, Board Chair and CEO
Sold 50.4% of holdings ($35.5M position)236,104 shares left9.6x usual sizeFiling
Every transaction
Loading transactions…
Sales and notices (19)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Feb 6, 2023 | Feb 8, 2023 | BMY | Board Chair and CEO | Form 4 sale | 240,000 | $17.9M | 50.4% | Unusual | SEC |
| Sep 20, 2022 | Sep 22, 2022 | BMY | Board Chair and CEO | Form 4 sale | 25,000 | $1.7M | 5.0% | Plan not stated | SEC |
| Sep 15, 2022 | Sep 16, 2022 | BMY | Board Chair and CEO | Form 4 sale | 50,000 | $3.6M | 9.1% | Plan not stated | SEC |
| Jun 13, 2022 | Jun 14, 2022 | BMY | Board Chair and CEO | Form 4 sale | 30,000 | $2.2M | 5.2% | Plan not stated | SEC |
| Mar 21, 2022 | Mar 23, 2022 | BMY | Board Chair and CEO | Form 4 sale | 25,000 | $1.8M | 4.1% | Plan not stated | SEC |
| Feb 24, 2022 | Feb 28, 2022 | BMY | Board Chair and CEO | Form 4 sale | 30,000 | $2M | 6.2% | Plan not stated | SEC |
| Sep 20, 2021 | Sep 22, 2021 | BMY | Board Chair and CEO | Form 4 sale | 25,000 | $1.5M | 4.9% | Plan not stated | SEC |
| Aug 2, 2021 | Aug 4, 2021 | BMY | Chairman and CEO | Form 4 sale | 20,000 | $1.4M | 3.8% | Plan not stated | SEC |
| Mar 22, 2021 | Mar 24, 2021 | BMY | Chairman and CEO | Form 4 sale | 25,000 | $1.6M | 4.5% | Plan not stated | SEC |
| Aug 31, 2020 | Sep 2, 2020 | BMY | Chairman and CEO | Form 4 sale | 39,840 | $2.5M | 8.2% | Plan not stated | SEC |
| May 3, 2016 | May 5, 2016 | BMY | Chief Executive Officer | Form 4 sale | 34,594 | $2.5M | 21.5% | Plan not stated | SEC |
| Feb 17, 2016 | Feb 19, 2016 | BMY | Chief Executive Officer | Form 4 sale | 12,040 | $766k | 13.6% | Plan not stated | SEC |
| Sep 15, 2014 | Sep 16, 2014 | BMY | Chief Operating Officer | Form 4 sale | 26,691 | $1.3M | 39.6% | Unusual | SEC |
| Feb 24, 2014 | Feb 25, 2014 | BMY | EVP & Chief Commercial Officer | Form 4 sale | 41,563 | $2.3M | 45.5% | Unusual | SEC |
| May 31, 2013 | May 31, 2013 | BMY | Pres., US Pharmaceuticals | Form 4 sale | 10,538 | $496k | 18.2% | Plan not stated | SEC |
| May 23, 2013 | May 23, 2013 | BMY | Pres., US Pharmaceuticals | Form 4 sale | 26,647 | $1.2M | 31.5% | Unusual | SEC |
| Feb 27, 2013 | Feb 27, 2013 | BMY | Pres., US Pharmaceuticals | Form 4 sale | 12,150 | $451k | 19.0% | Plan not stated | SEC |
| Jan 28, 2013 | Jan 28, 2013 | BMY | Pres., US Pharmaceuticals | Form 4 sale | 20,350 | $736k | 24.1% | Plan not stated | SEC |
| Aug 24, 2012 | Aug 28, 2012 | BMY | Pres., US Pharmaceuticals | Form 4 sale | 25,900 | $847k | 31.1% | Unusual | SEC |